Tarsus Pharmaceuticals, Inc. (TARS)
68.20
-3.88
(-5.38%)
USD |
NASDAQ |
Oct 23, 16:00
68.16
-0.04
(-0.06%)
After-Hours: 20:00
Tarsus Pharmaceuticals Enterprise Value : 2.590B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.590B |
| October 22, 2026 | 2.758B |
| October 21, 2026 | 2.690B |
| October 20, 2026 | 2.713B |
| October 19, 2026 | 2.646B |
| October 16, 2026 | 2.584B |
| October 15, 2026 | 2.711B |
| October 14, 2026 | 2.767B |
| October 13, 2026 | 2.703B |
| October 12, 2026 | 2.858B |
| October 09, 2026 | 2.805B |
| October 08, 2026 | 2.764B |
| October 07, 2026 | 2.824B |
| October 06, 2026 | 2.846B |
| October 05, 2026 | 2.861B |
| October 02, 2026 | 2.798B |
| October 01, 2026 | 2.904B |
| September 30, 2026 | 3.041B |
| September 29, 2026 | 2.957B |
| September 28, 2026 | 2.963B |
| September 25, 2026 | 2.914B |
| September 24, 2026 | 2.926B |
| September 23, 2026 | 2.854B |
| September 22, 2026 | 2.974B |
| September 21, 2026 | 2.991B |
| Date | Value |
|---|---|
| September 18, 2026 | 3.018B |
| September 17, 2026 | 3.059B |
| September 16, 2026 | 2.999B |
| September 15, 2026 | 3.024B |
| September 14, 2026 | 3.099B |
| September 11, 2026 | 3.071B |
| September 10, 2026 | 3.149B |
| September 09, 2026 | 3.221B |
| September 08, 2026 | 3.413B |
| September 04, 2026 | 3.567B |
| September 03, 2026 | 3.239B |
| September 02, 2026 | 3.220B |
| September 01, 2026 | 2.843B |
| August 31, 2026 | 2.851B |
| August 28, 2026 | 2.744B |
| August 27, 2026 | 2.751B |
| August 26, 2026 | 2.696B |
| August 25, 2026 | 2.731B |
| August 24, 2026 | 2.790B |
| August 21, 2026 | 2.785B |
| August 20, 2026 | 2.732B |
| August 19, 2026 | 2.817B |
| August 18, 2026 | 2.713B |
| August 17, 2026 | 2.695B |
| August 14, 2026 | 2.633B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 159.59B |
| Amneal Pharmaceuticals, Inc. | 9.247B |
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.55M |
| Revenue (Quarterly) | 173.91M |
| Total Expenses (Quarterly) | 192.46M |
| EPS Diluted (Quarterly) | -0.4275 |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -10.67% |
| Earnings Yield | -1.58% |
| Normalized Earnings Yield | -1.585 |